No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer

Japanese Journal of Cancer Research

Volumn 87, Issue 12, 1996, Pages 1280-1287

  Ohashi, Nobuyuki ^a   Fujiwara, Yasuhiro ^a   Yamaoka, Naoki ^a   Katoh, Osamu ^b   Satow, Yukio ^b   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

CPT 11; Lung cancer; Mrna expression; Point mutation; Topoisomerase I

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; MESSENGER RNA; TOPOTECAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030481460     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb03144.x     Document Type: Article

References (22)

1. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54, 1431-1439 (1994).
2. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C. and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 (1993).
3. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048 (1989).
4. Husaine, I., Mohler, J. L., Seigler, H. F. and Besterman, J. M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res., 54, 539-546 (1994).
5. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F. and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
6. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y. and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84, 5565-5569 (1987).
7. Kapoor, R., Slade, L., Fujimori, A., Pommier, Y. and Harker, W. G. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res., 7, 87-100 (1995).
8. Blin, N. and Stafford, D. M. A general method for isolation of high-molecular-weight DNA from eukaryotes. Nucleic Acids Res., 3, 2303-2308 (1976).
9. Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem., 162, 156-159 (1987).
10. Kawasaki, E. S., Clark, S. S., Coyne, M. Y., Smith, S. D., Champlin, R., Witte, O. N. and McCormick, F. P. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Natl. Acad. Sci. USA, 85, 5698-5702 (1988).
11. Mitsuhashi, M., Cooper, A., Ogura, M., Shinagawa, T., Yano, K. and Hosokawa, T. Oligonucleotide probe design - a new approach. Nature, 367, 759-761 (1994).
12. Kunze, N., Yang, G., Dolberg, M., Sundarp, R., Knippers, R. and Richter, A. Structure of the human type I DNA topoisomerase gene. J. Biol. Chem., 266, 9610-9616 (1991).
13. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y. and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55, 1339-1346 (1995).
14. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B. and Kufe, D. Identification of a mutant topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem., 269, 2433-2439 (1994).
15. Benedetti, P., Fiorani, P., Capuani, L. and Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res., 53, 4343-4348 (1993).
16. Tamura, H., Kohchi, C., Yamada, R., Ikeda, T., Koiwai, O., Patterson, E., Keene, J. D., Okada, K., Kjeldsen, E., Nishikawa, K. and Andoh, T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res., 19, 69-75 (1991).
17. Kubota, N., Kanzawa, F., Nishio, K., Takeda, Y., Ohmori, T., Fujiwara, Y., Terashima, Y. and Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
18. Iizuka, N., Oka, M., Noma, T., Nakazawa, A., Hirose, K. and Suzuki, T. NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res., 55, 652-657 (1995).
19. Andoh, T., Yasui, Y., Koiwai, O. and Okada, K. Molecular basis of resistance to CPT-11, a specific inhibitor of DNA topoisomerase I. In "The Mechanism and New Approach on Drug Resistance of Cancer Cells," ed. T. Miyazaki, F. Takaku and K. Sakuraba, pp. 95-101 (1993). Excepta Medica, Amsterdam.
20. Hayashi, K. and Yandell, D. W. How sensitive is PCR-SSCP? Hum. Mutat., 2, 338-346 (1993).
21. Niwa, K., Misao, R., Hanabayashi, T., Morishita, S., Murase, T., Itoh, M., Itoh, N., Mori, H. and Tamaya, T. Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative. Jpn. J. Cancer Res., 85, 869-874 (1994).
22. Sumiyoshi, H., Fujiwara, Y., Ohashi, N., Egusa, Y., Yamaoka, N. and Yamakido, M. Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 14, 457 (abstr. 1470) (1995).